Intravacc has enrolled the first participant in a phase I first in-human clinical trial of Avacc 10, the company’s SARS-CoV-2 intranasal subunit vaccine, as a booster shot.
Intranasal delivery of ChAdOx1 nCoV-19 failed to induce either a consistent mucosal antibody response or a strong systemic immune response, according to results from a Phase 1 clinical trial released today. However, researchers say delivery of vaccines...
A number of intranasal vaccines against COVID-19 are in development: hoping to provide a point of difference against authorized vaccines but also create a springboard for wider development against other respiratory diseases.
A clinical trial is exploring the use of the Oxford/AstraZeneca COVID-19 vaccine as an intranasal vaccine: seeing if the new route of administration could improve protection against infection and transmission.
CyanVac LLC and its subsidiary, Blue Lake Biotechnology, Inc., have enrolled the first participant in a Phase 1 clinical trial of their intranasal COVID-19 vaccine in Rochester, NY.
